60 Degrees Pharmaceuticals (NASDAQ:SXTP), a specialist in medicines for vector-borne diseases, announced Wednesday that all three patients enrolled in its expanded-use clinical trial for relapsing babesiosis were successfully cured.
The results, when combined with prior data from a 2024 Yale School of Public Health report, demonstrate a near 100% cure rate across seven patients treated with a combination regimen featuring tafenoquine.
The study focused on highly vulnerable, immunosuppressed patients who had previously failed standard antimicrobial therapies.
The treatment protocol involved a weekly dose of tafenoquine added to atovaquone-containing combinations, sustained until patients achieved two consecutive negative molecular tests.
Clinical resolution was confirmed using high-sensitivity RNA amplification tests alongside standard PCR assays to ensure the complete eradication of the Babesia microti parasite.
Currently, the FDA has not approved any specific drug for the treatment of babesiosis.
While tafenoquine is marketed in the U.S. as ARAKODA for malaria prophylaxis, its use in treating babesiosis remains investigational.